[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Feng Gao\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":140},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,66,92,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100639150","efficacy-and-safety-of-bailout-intracranial-angioplasty-or-stenting-after-thrombectomy-for-acute-intracranial-atherosclerotic-large-vessel-occlusion-angel-reboot-2-100639150",false,"NCT07618052","Efficacy and Safety of Bailout Intracranial Angioplasty or Stenting After Thrombectomy for Acute Intracranial Atherosclerotic Large Vessel Occlusion (ANGEL-REBOOT 2)","Efficacy and Safety of Bailout Intracranial Angioplasty or Stenting After Thrombectomy for Acute Intracranial Atherosclerotic Large Vessel Occlusion: A Clinical Trial Combining a Randomized Controlled Trial and a Concurrent Prospective Observational Cohort","Inclusion Criteria:\n\n1. Age≥18 years.\n2. Time interval from symptom onset to puncture ≤24 hours.\n3. National Institute of Health Stroke Scale (NIHSS) Score ≥6 before randomisation.\n4. Pre-stroke modified Rankin Scale (mRS) of 0-2.\n5. Each patient or their legal representative must provide written informed consent before enrolment.\n\nImaging Inclusion Criteria:\n\n1. For patients with anterior circulation stroke, a CT or DWI-based Alberta Stroke Program Early CT Score (ASPECTS) of ≥6 is required.\n2. For patients with posterior circulation stroke, CT or DWI-based posterior circulation ASPECTS (pc-ASPECTS) of ≥6 and Pons-Midbrain Index (PMI) of \\\u003C3 are required.\n\nAngiographic Inclusion Criteria:\n\n1. Acute ischemic stroke (AIS) resulting from large vessel occlusion (LVO) involving the intracranial internal carotid artery, the M1 segment of the middle cerebral artery, the V4 segment of the vertebral artery, or the basilar artery, with high suspicion of intracranial atherosclerotic stenosis-related large-vessel occlusion (ICAS-LVO).\n2. Part 1 (RCT): Successful recanalization of the occluded artery (eTICI ≥ 2b) with residual stenosis ≥ 70% after 1-2 thrombectomy attempts.\n\n   Part 2 (Prospective observational cohort): Failure to achieve successful recanalization (eTICI 0-2a) after at least two thrombectomy attempts. All other inclusion criteria are identical to those for Part 1.\n3. Occluded artery amenable to angioplasty (balloon dilation and\u002For stenting) by the judgement of the treating neurointerventionalist.\n\nExclusion Criteria:\n\n1. Any sign of intracranial hemorrhage (ICH, except microbleeds) on baseline brain imaging.\n2. CT or MR imaging evidence of intracranial tumor (except small meningiomas or cerebral aneurysms \\\u003C 3mm in diameter).\n3. Any indication of intracranial vessel perforation during thrombectomy..\n4. Presence of tandem lesion in the extracranial segment of the internal carotid artery or vertebral artery, or intracranial arterial stenosis with distal vessel occlusion..\n5. Stenosis caused by non-atherosclerotic intracranial arteriopathies (e.g., autoimmune vasculitis, vasospasm, cerebral artery dissection).\n6. Evidence of cardioembolism (e.g., atrial fibrillation, prosthetic heart valve, infective endocarditis, mitral stenosis, atrial myxoma, intracardiac thrombus\u002Fvegetation, left ventricular aneurysm, etc.).\n7. Contraindication for antiplatelet treatment.\n8. Excessive vascular tortuosity or anatomical variants that may preclude successful delivery or positioning of interventional devices.\n9. History of contraindication to the use of contrast medium.\n10. Refractory hypertension (defined as systolic blood pressure\\>185 mmHg or diastolic blood pressure\\>110 mmHg) that cannot be controlled by drug treatment.\n11. Known hereditary or acquired bleeding tendency, lack of coagulation factors, or oral anticoagulants with INR\\>1.5.\n12. Blood glucose\\\u003C2.8 or\\>22.2 mmol\u002FL; Platelet count\\\u003C100\\*109\u002FL, serum creatinine\\>2.0 g\u002FL (177 μ mol\u002FL), or glomerular filtration rate\\\u003C30 ml\u002F(min\\*1.73 m2).\n13. Concurrent participation in another drug or device trial, or expected participation within the following 3 months.\n14. Patients whose life expectancy is less than 1 year (such as patients with malignant tumor, advanced cardiopulmonary disease, etc.).\n15. Known pregnancy or lactation, or positive pregnancy test before randomization (or before enrollment).\n16. Known dementia or psychiatric disorder that precludes completion of neurological assessments and follow-up.\n17. Any other condition deemed by the site investigator to make the patient unsuitable for participation.","ALL","18 Years",{"count":19,"type":20},420,"ESTIMATED","INTERVENTIONAL",[23],"NA","A multicenter, randomized, open-label, blinded-endpoint trial with a concurrent prospective observational cohort to compare bailout intracranial angioplasty or stenting versus standard therapy on functional outcome, stroke recurrence, and mortality in patients with acute intracranial atherosclerotic stenosis-related large vessel occlusion after thrombectomy.",[26,27,28],"Intracranial Atherosclerotic Stenosis-Related Large Vessel Occlusion","Acute Ischemic Stroke","Bailout Angioplasty or Stenting",[30,31,28],"Acute Intracranial Atherosclerotic Stenosis-Related Large Vessel Occlusion","Endovascular Thrombectomy","NOT_YET_RECRUITING","2026-05-25",{"date":35,"type":36},"2026-06-01","ACTUAL",{"date":35,"type":20},{"date":39,"type":20},"2028-06-01",{"name":41,"class":42},"Feng Gao","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":63,"leadSponsor":65,"locationsCount":43},"100635807","randomized-clinical-trial-of-endovascular-treatment-for-progressive-stroke-with-vertebrobasilar-artery-occlusion-100635807","NCT07557485","Randomized Clinical Trial of Endovascular Treatment for Progressive Stroke With Vertebrobasilar Artery Occlusion","Safety and Efficacy of Endovascular Treatment for Progressive Stroke Due to Vertebrobasilar Artery Occlusion: A Multicenter, Prospective, Open-Label Randomized Controlled Trial With Blinded Endpoint Assessment","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Acute ischemic stroke, with a National Institutes of Health Stroke Scale (NIHSS) score of \\\u003C10 at initial symptom onset, and no prior endovascular treatment.\n3. Stroke progression occurring from 24 hours to 14 days after initial symptom onset, defined as an NIHSS score of ≥10 with an increase of ≥4 points from baseline.\n4. Acute basilar artery occlusion or dominant vertebral artery occlusion with contralateral occlusion or hypoplasia, confirmed by CTA, MRA or DSA.\n5. Posterior circulation Alberta Stroke Program Early CT Score (pc-ASPECTS) of ≥6 and Pons-Midbrain Index (PMI) of ≤3 on CT or diffusion-weighted imaging (DWI).\n6. Randomization within 24 hours of stroke progression.\n7. Pre-stroke mRS score of 0-2.\n8. Provision of signed informed consent by the patient or their legal representative.\n\nExclusion Criteria:\n\n1. Any sign of intracranial hemorrhage (except microbleeds) on baseline brain imaging.\n2. Imaging confirms the progression of symptoms caused by intracranial hemorrhage, brain edema, or other clear causes.\n3. Extensive cerebellar infarction with significant mass effect or bilateral thalamic infarction on baseline neuroimaging.\n4. Presence of untreated intracranial aneurysm, intracranial tumor (except small meningioma and aneurysms \\\u003C3 mm in diameter), or intracranial arteriovenous malformation.\n5. Known or highly suspected chronic responsible artery occlusion.\n6. Presence of severe stenosis in the extracranial or intracranial segment of the responsible artery, arterial dissection, or excessive vascular tortuosity that may prevent successful delivery or navigation of endovascular devices.\n7. Known contraindication to contrast medium (except mild rash).\n8. Refractory hypertension not controlled by medication, defined as systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg.\n9. Known pregnancy or lactation, or a positive pregnancy test prior to randomization.\n10. Known dementia or psychiatric disease precluding completion of neurological assessment and follow-up.\n11. Life expectancy \\\u003C1 year, including patients with malignancy or advanced cardiopulmonary disease.\n12. Current participation in any other clinical trial of drugs or medical devices, or anticipated participation in another such trial within 3 months after enrollment.\n13. Acute ischemic stroke within 48 hours after cardiovascular or cerebrovascular interventional treatment or major surgery; patients presenting \\>48 hours after such procedures were eligible.\n14. Recent (within 1 month) gastrointestinal or genitourinary bleeding, acute myocardial infarction, or traumatic brain injury.\n15. Multivessel severe stenosis or occlusion confirmed by CTA, MRA, or DSA.\n16. Known or suspected central nervous system vasculitis.\n17. Known hereditary or acquired bleeding diathesis, coagulation factor deficiency, current use of oral anticoagulants with an INR \\>1.5, or active bleeding.\n18. Blood glucose \\\u003C2.8 or \\>22.2 mmol\u002FL; platelet count \\\u003C100 × 10⁹\u002FL; estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m² or serum creatinine ≥177 μmol\u002FL (2.0 mg\u002FdL).\n19. Any other condition deemed by the site investigator to make the patient unsuitable for participation.",{"count":52,"type":20},240,[23],"This multicenter, prospective, open-label randomized controlled trial with blinded assessment was designed to assess the efficacy and safety of endovascular treatment for progressive stroke due to vertebrobasilar artery occlusion.",[56,57],"Vertebrobasilar Artery Occlusion","Endovascular Treatment",[27,56,57],"2026-04-23",{"date":61,"type":36},"2026-04-29",{"date":35,"type":20},{"date":64,"type":20},"2029-12-31",{"name":41,"class":42},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":43},"100631076","randomized-clinical-trial-of-endovascular-recanalization-for-symptomatic-non-acute-intracranial-artery-occlusionrepair-100631076","NCT07495969","Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR）","Endovascular Recanalization Versus Aggressive Medical Management Alone for Symptomatic Non-Acute Intracranial Artery Occlusion: A Multicenter, Prospective, Open-Label, Endpoint-Blinded, Randomized Controlled Clinical Trial","Clinical inclusion criteria:\n\n1. Age ranging between 18 and 80 years.\n2. Ischemic events (TIA or ischemic stroke) related to the occluded artery, occurring despite aggressive medical management, with the last event occurring within between 14 and 90 days prior to enrollment.\n3. The modified Rankin Scale (mRS) score 0-2 at the time of enrollment.\n4. At least one risk factor for atherosclerosis.\n5. All enrolled patients refused bypass surgery.\n6. Signatured informed consent form.\n\nImaging inclusion criteria:\n\n1. Occlusion of intracranial ICA, M1 segment of MCA, intracranial VA (with contralateral VA hypoplasia or occlusion), or BA, as confirmed by CT angiography (CTA) or digital subtraction angiography (DSA), and the length of the cclusion segment was≤15mm.\n2. A decrease of \\>30% in cerebral blood flow in the territory distal to the target region, as assessed by CT perfusion (CTP); or inadequate collateral compensation indicated by digital subtraction angiography (DSA), defined as an ASITN\u002FSIR collateral grade of 0-2; or evidence of hemodynamic ischemic lesions on CT or MRI.\n3. Alberta Stroke Program Early CT Score (ASPECTS) ≥ 6 for anterior circulation occlusion, or posterior circulation ASPECTS (pc-ASPECTS) ≥ 6 and pons-midbrain index (PMI) \\\u003C 3 for posterior circulation occlusion, as demonstrated by CT or MRI.\n4. Technical feasibility of endovascular recanalization (ER) in the qualifying artery evaluated by two experienced interventional neuroradiologists.\n\nExclusion Criteria:\n\n1. Severe stenosis (70%-99%) or occlusion of other arteries, or tandem stenosis (70%-99%) that is proximal to the qualifying artery.\n2. Intracranial hemorrhagic diseases such as definite Intracranial tumors, any intracranial vascular malformations, hemorrhagic transformation of infarction, spontaneous intracranial hemorrhage (cerebral parenchymal, subarachnoid, subdural, or epidural) within 30 days.\n3. Non atherosclerotic intracranial artery disease: arterial dissection, moyamoya disease or moyamoya syndrome demonstrated by imaging examination, or a definite medical history of autoimmune vasculitis.\n4. Evidence of cardioembolic embolism such as atrial fibrillation, prosthetic valve(s), infective endocarditis, mitral stenosis, atrial myxoma, intracardiac clot or vegetation, left ventricular aneurysms, etc.\n5. Known unstable angina or myocardial infarction within the last 6 months.\n6. Intolerance or allergic reaction to any treatment-related medication, including aspirin, clopidogrel, heparin, and local or general anesthetics.\n7. History of life-threatening allergy to contrast dye.\n8. Severe liver impairment (AST or ALT \\> 3 times normal, cirrhosis), serum creatinine \\> 3.0 mg\u002Fdl.\n9. Past history of EC-IC bypass surgery or EVT.\n10. Major surgery (including open femoral, aortic, or carotid surgery) within previous 30 days or planned in the next 90 days after enrollment.\n11. Late-stage malignant tumors, cachexia, or other serious diseases and an expected life expectancy of less than 1 year.\n12. Pregnant, perinatal stage or lactating women.\n13. Any other condition (in the opinion of the site investigator) that inappropriate to participate this study.","80 Years",{"count":75,"type":20},286,[23],"A multicenter, randomized, open-label, endpoint-blinded trial to compare the effects of endovascular recanalization plus aggressive medical management with aggressive medical management alone on stroke recurrence and mortality in patients with symptomatic non-acute intracranial artery occlusion.",[79,80],"Symptomatic Non-acute Intracranial Artery Occlusion","Ischemic Stroke",[82,83],"Endovascular Recanalization","Symptomatic Non-acute intracranial artery occlusion","2026-03-22",{"date":86,"type":36},"2026-03-27",{"date":88,"type":20},"2026-04-01",{"date":90,"type":20},"2028-12-31",{"name":41,"class":42},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":101,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":113,"locationsCount":43},"100622931","the-efficacy-and-safety-of-endovascular-treatment-for-acute-mild-basilar-artery-occlusion-100622931","NCT07390032","The Efficacy and Safety of Endovascular Treatment for Acute Mild Basilar Artery Occlusion","The Efficacy and Safety of Endovascular Treatment for Acute Mild Basilar Artery Occlusion: A Multicenter, Prospective, Open-Label, Endpoint-Blinded, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Age≥18\n2. Acute ischemic stroke in posterior circulation, the time from stroke onset (or finally found normal) to randomization was within 24 hours\n3. Acute basilar artery occlusion confirmed by CTA,MRA,or DSA\n4. NIHSS score≥2 points and\\\u003C10 points from the onset of the disease to before randomization\n5. Posterior circulation large core infarction:NCCT or DWI showed pc-ASPECTS≥6, or Pons-Midbrain Index (PMI)\\\u003C3\n6. No significant functional disability before stroke (mRS≤2 points)\n7. Each patient or their legal representative must provide written informed consent before enrolment\n\nExclusion Criteria:\n\n1. Any sign of intracranial hemorrhage (except microbleeds) on brain imaging prior to randomization\n2. Complete cerebellar infarct with significant mass effect, or bilateral thalamic infarction as evidenced by baseline neuroimaging\n3. Known or highly suspected chronic occlusion of basilar artery\n4. History of contraindication for contrast medium (except mild rash)\n5. CTA\u002FMRA\u002FDSA confirmed occlusion of anterior and posterior circulation\n6. Severe stenosis, arterial dissection, or excessive tortuosity of the extracranial or intracranial segments of the vertebral artery may result in the inability of interventional instruments to be successfully delivered or positioned\n7. Current pregnant or breast-feeding\n8. Refractory hypertension (defined as systolic blood pressure\\>185 mmHg or diastolic blood pressure\\>110 mmHg) that cannot be controlled by drug treatment\n9. Known hereditary or acquired bleeding tendency, lack of coagulation factors, or oral anticoagulants with INR\\>1.5\n10. Blood glucose\\\u003C2.8 or\\>22.2 mmol\u002FL; Platelet count\\\u003C100\\*109\u002FL, serum creatinine\\>2.0 g\u002FL (177 μ mol\u002FL), or glomerular filtration rate\\\u003C30 ml\u002F(min\\*1.73 m2)\n11. Enrolled in another drug or device trial or expected to participate in another drug or device treatment trial within the following 3 months\n12. Acute cerebral infarction occurred within 48 hours after cardio cerebral vascular intervention or major surgery (patients over 48 hours can be included in the group)\n13. Patients whose life expectancy is less than 1 year (such as patients with malignant tumor, advanced cardiopulmonary disease, etc.)\n14. Central nervous system vasculitis has been diagnosed or clinically suspected\n15. Known to have dementia or psychiatric disease unable to complete neurological assessment and follow-up\n16. It is known that patients with dementia or mental illness cannot complete neurological function assessment and follow-up\n17. Any other condition (in the opinion of the site investigator) that inappropriate to participate this study",{"count":100,"type":20},230,[23],"This study assesses the efficacy and safety of endovascular treatment for acute mild basilar artery occlusion within a multicenter, prospective, open-label, endpoint-blinded, randomized controlled clinical trial.",[104,105,57],"Acute Mild Basilar Artery Occlusion","Basilar Artery Occlusion",[27,104,105,57],"2026-01-28",{"date":109,"type":36},"2026-02-05",{"date":111,"type":20},"2026-03-01",{"date":64,"type":20},{"name":41,"class":42},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":21,"phases":124,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":4},"100575520","phase-4-a-response-surface-analysis-for-the-interaction-between-ciprofol-and-sevoflurane-100575520","NCT06773351","A Response Surface Analysis for the Interaction Between Ciprofol and Sevoflurane","A Response Surface Analysis for the Interaction Between Ciprofol and Sevoflurane During Anesthesia Induction","Inclusion Criteria:\n\n* Patients undergoing elective general anesthesia and non-cardiac surgery;\n* Age 18-60 years old, gender is not limited;\n* ASA I or II level;\n* Body mass index (BMI) 18-30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Preoperative assessment of potential difficult airway risk;\n* Airway hyperreactivity;\n* There is disease of the central nervous system or cardiovascular system;\n* Currently using drugs that may alter the pharmacokinetics and pharmacokinetics of the drug under study;\n* Known or suspected allergy or contraindication to the components or regimens of the investigational drug;\n* A history of drug or alcohol addiction;\n* Patients with gastroesophageal reflux disease;\n* Severe liver and kidney dysfunction.","60 Years",{"count":123,"type":20},300,[125],"PHASE4","Intravenous and inhalation combined anesthesia is a commonly used method for maintaining general anesthesia in clinical practice. This study aims to explore the interaction between ciprofol and sevoflurane. By employing response surface methodology, we constructed a three-dimensional pharmacodynamic interaction surface for various dose combinations of ciprofol and sevoflurane. This approach allows us to determine the nature of the interaction between the two drugs at any given level, thereby providing a ciprofol understanding of the dose-response relationship when ciprofol and sevoflurane are used in combination. This knowledge will serve as a theoretical basis for rational drug administration during surgery.",[128],"Induction of General Anesthesia",[130,131],"ciprofol","response surface analysis","2025-01-13",{"date":134,"type":36},"2025-01-14",{"date":136,"type":20},"2025-02-01",{"date":138,"type":20},"2025-12-31",{"name":41,"class":42},""]